Metabolic dysfunction–associated steatotic liver disease (MASLD) is the most common chronic liver condition. MASLD is a sexually dimorphic condition, with its development and progression influenced by sex chromosomes and hormones. Estrogens typically protect against, whereas androgens promote, MASLD. Therapeutic approaches for a sex-specific personalized medicine include estrogen replacement, androgen blockers, and novel drugs targeting hormonal pathways. However, the interactions between hormonal factors and inherited genetic variation impacts MASLD risk, necessitating more tailored therapies. Understanding sex disparities and the role of estrogens could improve MASLD interventions and management, whereas clinical trials addressing sex differences are crucial for advancing personalized treatment. This review explores the underappreciated impact of sexual dimorphism in MASLD and discusses the potential therapeutic application of sex-related hormones.

Sexual dimorphism of metabolic dysfunction-associated steatotic liver disease / A. Cherubini, S. DELLA TORRE, S. Pelusi, L. Valenti. - In: TRENDS IN MOLECULAR MEDICINE. - ISSN 1471-4914. - (2024), pp. S1471-4914(24)00135-7.1-S1471-4914(24)00135-7.11. [Epub ahead of print] [10.1016/j.molmed.2024.05.013]

Sexual dimorphism of metabolic dysfunction-associated steatotic liver disease

A. Cherubini
Primo
;
S. DELLA TORRE
Secondo
;
S. Pelusi
Penultimo
;
L. Valenti
Ultimo
2024

Abstract

Metabolic dysfunction–associated steatotic liver disease (MASLD) is the most common chronic liver condition. MASLD is a sexually dimorphic condition, with its development and progression influenced by sex chromosomes and hormones. Estrogens typically protect against, whereas androgens promote, MASLD. Therapeutic approaches for a sex-specific personalized medicine include estrogen replacement, androgen blockers, and novel drugs targeting hormonal pathways. However, the interactions between hormonal factors and inherited genetic variation impacts MASLD risk, necessitating more tailored therapies. Understanding sex disparities and the role of estrogens could improve MASLD interventions and management, whereas clinical trials addressing sex differences are crucial for advancing personalized treatment. This review explores the underappreciated impact of sexual dimorphism in MASLD and discusses the potential therapeutic application of sex-related hormones.
MASLD, NAFLD, fatty liver disease, estrogen receptor, hormones;
Settore BIO/10 - Biochimica
Settore BIO/14 - Farmacologia
Settore MED/09 - Medicina Interna
   Disentangling genetic, epigenetic and hormonal regulation of Fe/heme metabolism in the gender-specific nature of NAFLD (DEFENDER)
   DEFENDER
   MINISTERO DELL'UNIVERSITA' E DELLA RICERCA
   2022XJNWRM_001

   Neuronal microscopy for cell behavioural examination and manipulation
   REVEAL
   European Commission
   Horizon 2020 Framework Programme
   101016726

   Understanding Gene ENvironment Interaction in ALcohol-related hepatocellular carcinoma (GENIAL)
   GENIAL
   EUROPEAN COMMISSION
   101096312
2024
17-giu-2024
Article (author)
File in questo prodotto:
File Dimensione Formato  
TRendsMolecMed 2024.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 1.31 MB
Formato Adobe PDF
1.31 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/1064269
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact